130 related articles for article (PubMed ID: 7680874)
21. Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate.
List AF; Kummet TD; Adams JD; Chun HG
Am J Med; 1990 Sep; 89(3):388-90. PubMed ID: 1697447
[No Abstract] [Full Text] [Related]
22. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report.
Sorensen JM; Vena DA; Fallavollita A; Chun HG; Cheson BD
J Clin Oncol; 1997 Feb; 15(2):458-65. PubMed ID: 9053466
[TBL] [Abstract][Full Text] [Related]
23. From the Food and Drug Administration.
Nightingale SL
JAMA; 1991 Jul; 266(2):190. PubMed ID: 1711593
[No Abstract] [Full Text] [Related]
24. A human B-cell CLL model established by transplantation of JOK-1 cells into SCID mice and an anti-leukemia efficacy of fludarabine phosphate.
Bai L; Kon K; Tatsumi M; Ito H; Hayashi S; Brautigam M
Oncol Rep; 2000; 7(1):33-8. PubMed ID: 10601587
[TBL] [Abstract][Full Text] [Related]
25. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia.
Keating MJ
Semin Oncol; 1990 Oct; 17(5 Suppl 8):49-62. PubMed ID: 1699283
[TBL] [Abstract][Full Text] [Related]
26. More on purine analog-induced apoptosis in B cell chronic lymphocytic leukemia.
Morabito F; Filangeri M; Sculli G; Oliva B
Leukemia; 1998 Apr; 12(4):633-5. PubMed ID: 9557625
[No Abstract] [Full Text] [Related]
27. Fludarabine for prolymphocytic leukaemia and risk of interstitial pneumonitis.
Cervantes F; Salgado C; Montserrat E; Rozman C
Lancet; 1990 Nov; 336(8723):1130. PubMed ID: 1700245
[No Abstract] [Full Text] [Related]
28. Fludarabine monophosphate in refractory B-chronic lymphocytic leukemia: maintenance may be significant to sustain response.
Angelopoulou MA; Poziopoulos C; Boussiotis VA; Kontopidou F; Pangalis GA
Leuk Lymphoma; 1996 Apr; 21(3-4):321-4. PubMed ID: 8726414
[TBL] [Abstract][Full Text] [Related]
29. Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia.
Schilling PJ; Vadhan-Raj S
N Engl J Med; 1990 Sep; 323(12):833-4. PubMed ID: 1697401
[No Abstract] [Full Text] [Related]
30. Fludarabine phosphate in refractory hairy cell leukemia.
Kraut EH; Chun HG
Am J Hematol; 1991 May; 37(1):59-60. PubMed ID: 1708945
[TBL] [Abstract][Full Text] [Related]
31. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia.
Keating MJ; Kantarjian H; Talpaz M; Redman J; Koller C; Barlogie B; Velasquez W; Plunkett W; Freireich EJ; McCredie KB
Blood; 1989 Jul; 74(1):19-25. PubMed ID: 2473795
[TBL] [Abstract][Full Text] [Related]
32. [Fludarabine monophosphate in the treatment of patients with advanced stages of chronic B-cell lymphatic leukemia resistant to conventional chemotherapy].
Papajík T; Faber E; Hubácek J; Slezák P; Raida L; Heczko M; Sulovská I; Jarosová M; Pikalová Z; Indrák K
Vnitr Lek; 1997 Jan; 43(1):25-8. PubMed ID: 9221561
[TBL] [Abstract][Full Text] [Related]
33. Fludarabine phosphate (Fludara).
Betcher DL; Burnham N
J Pediatr Oncol Nurs; 1992 Apr; 9(2):87-9. PubMed ID: 1375832
[No Abstract] [Full Text] [Related]
34. Lysis pneumonopathy associated with the use of fludarabine phosphate.
Crowley JJ; Knight L; Charan N
West J Med; 1994 Dec; 161(6):597-9. PubMed ID: 7531920
[No Abstract] [Full Text] [Related]
35. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma.
Foran JM; Rohatiner AZ; Coiffier B; Barbui T; Johnson SA; Hiddemann W; Radford JA; Norton AJ; Tollerfield SM; Wilson MP; Lister TA
J Clin Oncol; 1999 Feb; 17(2):546-53. PubMed ID: 10080598
[TBL] [Abstract][Full Text] [Related]
36. [Phase II clinical study of SH L 573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia].
Miyawaki S; Imamura M; Kobayashi S; Ohnishi K; Hodohara K; Mizoguchi H; Tomonaga M; Tango T; Ohno R
Rinsho Ketsueki; 1999 Dec; 40(12):1236-44. PubMed ID: 10658476
[TBL] [Abstract][Full Text] [Related]
37. Fludarabine monophosphate as salvage for refractory chronic lymphocytic leukaemia.
Pillay GS; Wood L; Jacobs P
S Afr Med J; 1996 Aug; 86(8):949-51. PubMed ID: 8823419
[TBL] [Abstract][Full Text] [Related]
38. Fludarabine phosphate: a new active agent in hematologic malignancies.
Keating MJ; O'Brien S; Plunkett W; Robertson LE; Gandhi V; Estey E; Dimopoulos M; Cabanillas F; Kemena A; Kantarjian H
Semin Hematol; 1994 Jan; 31(1):28-39. PubMed ID: 7510070
[No Abstract] [Full Text] [Related]
39. A comprehensive phase I and II clinical investigation of fludarabine phosphate.
Grever M; Leiby J; Kraut E; Metz E; Neidhart J; Balcerzak S; Malspeis L
Semin Oncol; 1990 Oct; 17(5 Suppl 8):39-48. PubMed ID: 1699282
[TBL] [Abstract][Full Text] [Related]
40. A sensitive fluorescence assay for quantitation of fludarabine and metabolites in biological fluids.
Kemena A; Fernandez M; Bauman J; Keating M; Plunkett W
Clin Chim Acta; 1991 Aug; 200(2-3):95-106. PubMed ID: 1723357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
